Journal of Pharmaceutical Negative Results

REVIEW ARTICLE
Year
: 2019  |  Volume : 10  |  Issue : 1  |  Page : 1--5

Unsuccessful story of ABT-639 in neuropathic pain in different phases of clinical trials


Jasmine Sharma, Nirmal Singh, Amteshwar Singh Jaggi 
 Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India

Correspondence Address:
Amteshwar Singh Jaggi
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala - 147 002, Punjab
India

Neuropathic pain is a chronic pain state caused by injury of the nervous system, and there are various conditions associated with it such as diabetic neuropathy, postherpetic neuralgia, cancer pain, trigeminal neuralgia, cervical radiculopathy, and anticancer and anti-HIV-induced neuropathic pain. The pathophysiological role of voltage-gated T-type calcium channels in neuropathic pain has been well documented. ABT-639 is a peripherally acting, selective T-type calcium channel blocker, and it is shown to efficiently reduce nociceptive and neuropathic pain in rats in multiple models. However, three clinical studies exploring the role of single dose or multiple doses of ABT-639 (100 mg) in diabetic neuropathy have not found significant pain-attenuating actions. The present review discusses the unsuccessful clinical trials of peripherally acting ABT-639 in patients with diabetic neuropathy.


How to cite this article:
Sharma J, Singh N, Jaggi AS. Unsuccessful story of ABT-639 in neuropathic pain in different phases of clinical trials.J Pharm Negative Results 2019;10:1-5


How to cite this URL:
Sharma J, Singh N, Jaggi AS. Unsuccessful story of ABT-639 in neuropathic pain in different phases of clinical trials. J Pharm Negative Results [serial online] 2019 [cited 2019 Sep 23 ];10:1-5
Available from: http://www.pnrjournal.com/article.asp?issn=0976-9234;year=2019;volume=10;issue=1;spage=1;epage=5;aulast=Sharma;type=0